Comparison of the Toxicity of a Single Session versus Multiple Radiation Therapy Sessions for the Treatment of Metastases
Summary description of the study
Since the 1990s, a radiation technique known as stereotactic body radiation therapy (SBRT) has been used for the local treatment of metastases, particularly in the brain, bones, lungs, liver, neck, lymph nodes, or other soft tissues. There are various ways to perform SBRT. In most cases, each metastasis is treated by administering a low radiation dose multiple times in succession, a technique referred to as SBRT with multiple fractions. Another technique involves administering a high radiation dose in a single session. Although this technique, known as SBRT with single fraction, may have several advantages (i.e., fewer hospital visits, less financial and logistical burden), it is still rarely used in clinical practice. In this sub-study, we investigate whether the administration of a high radiation dose in a single session (i.e., SBRT with single fraction) is as safe and effective for the treatment of oligometastases as the administration of several lower radiation doses (i.e., SBRT with multiple fractions).
(BASEC)
Intervention under investigation
We investigate whether the administration of a high radiation dose in a single session (i.e., SBRT with single fraction) is as safe and effective for the treatment of oligometastases as the administration of several lower radiation doses (i.e., SBRT with multiple fractions).
(BASEC)
Disease under investigation
oligometastatic tumor disease
(BASEC)
oligometastatic tumor disease, a condition where cancer has spread from its original site to other parts of the body (new tumors referred to as oligometastases) (BASEC)
Exclusion criteria
None (BASEC)
Trial sites
Bern, Zurich
(BASEC)
Sponsor
not available
Contact
Contact Person Switzerland
Prof. Dr. med. Matthias Guckenberger
+41442552930
Matthias.Guckenberger@clutterusz.ch(BASEC)
Scientific Information
not available
Name of the authorising ethics committee (for multicentre studies, only the lead committee)
Ethics Committee Zurich
(BASEC)
Date of authorisation
14.03.2025
(BASEC)
ICTRP Trial ID
not available
Official title (approved by ethics committee)
not available
Academic title
not available
Public title
not available
Disease under investigation
not available
Intervention under investigation
not available
Type of trial
not available
Trial design
not available
Inclusion/Exclusion criteria
not available
not available
Primary and secondary end points
not available
not available
Registration date
not available
Incorporation of the first participant
not available
Secondary sponsors
not available
Additional contacts
not available
Secondary trial IDs
not available
Results-Individual Participant Data (IPD)
not available
Further information on the trial
not available
Results of the trial
Results summary
not available
Link to the results in the primary register
not available